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1. Abstract
Tumour metastasis to the brain is a complex pro-
cess involving crosstalk between the circulating tumour
cells and the blood brain barrier (BBB). Astrocytes, which
reside in the abluminal surface of the microvasculature of
the BBB, are now known to play an essential role in tumour
cell migration and invasion into the brain parenchyma. For
instance, pro-inflammatory astrocyte secretions, including
TNF-α, IL-6, CXCL10 as well as polyunsaturated fatty
acids interact with circulating tumour cells to promote mi-
gration and proliferation. Additionally, astrocyte and tu-
mour cell derived MMPs play a vital role in tumour cell
invasion through the BBB. Understanding these complex
interactions between tumour cells and astrocytes in the tu-
mourmicroenvironment may contribute to the development
of novel therapeutics for brain metastasis. Therefore, in this
review, we present key interactions within the neurovascu-
lar unit of the BBB in the tumour microenvironment that
significantly aids cancer metastasis, focusing particularly
on astrocytes.
2. Introduction
It is estimated that cancer will affect 4 million peo-
ple in the UK by 2030, an increase from 2.1 million today
[1]. Metastasis to the brain involves tumour cells detach-
ing from the primary tumour site by degrading the extracel-
lular matrix (ECM) and entering circulation, followed by
arrest and extravasation into a distant organ with the sub-
sequent formation of secondary metastatic lesions [2]. One
of the most common type of primary cancer that gives rise
to brain metastases is the lung, with nearly 65% of patients
estimated to develop this complication [3]. Breast carci-
noma and melanoma are other known predominant cases
of brain metastasis [4]. Despite brain metastasis being the
most common of intracranial tumours, treatment options are
limited, with chemotherapy proving clinically ineffective
in patients with secondary metastatic brain lesions due to
the inability of the drugs to penetrate the BBB [5]. There-
fore, brain metastasis has a poor prognosis and is a signif-
icant contributor to mortality in patients [6], with the me-
dian survival rate ranging from 9 to 15 months [7]. This
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Fig. 1. Structure of the blood brain barrier (BBB), also known as the neurovascular unit, consisting of astrocytic end feet on the abluminal side
of the capillary endothelium in close proximity with pericytes also coating the endothelium.
highlights the urgency to understand the mechanisms un-
derlying tumour cell entry through the BBB and the sub-
sequent rise of secondary lesions. Although rare (3%–5%
incidence), brain tumours can metastasise from the brain to
other organs, known as extraneural metastases. This can oc-
cur through lymphatic drainage, invasion through the dura
or bone or invasion through the venous system [8]. How-
ever, extraneural metastases is resisted through the lack
of ECM proteins in the central nervous system as well as
the capillary basement membrane being a physical barrier
against metastases migrating into the blood stream [9]. As
the severity remains higher for cancer cells metastasising
to the brain, this emphasises the need to explore the mech-
anisms underlying brain metastasis. Although numerous
studies have reported the overall extravasation of circulat-
ing tumour cells (CTCs) into the brain, the molecular and
cellular basis of this mechanism remains largely unknown.
Therefore, in this review, we aim to present the current
understanding of the molecular interactions and crosstalk
between the components of the BBB including endothe-
lial cells, astrocytes and pericytes along with CTCs in the
blood-tumour barrier (BTB) that may contribute to the po-
tential development of treatments for this deadly disease.
3. The structure of the blood brain barrier
The BBB is a selective, partially permeable barrier
formed of endothelial cells that tightly regulate the trans-
port of ionic and fluid molecules into or from the cerebral
microvasculature and brain parenchyma [10]. With tight-
junctions and the compact structure of the endothelium,
the BBB provides optimal conditions for neuronal function
through the regulation of ionic traffic and protection from
ionic fluctuations [11]. The fundamental structure of the
BBB consists of endothelial cells, astrocytes and pericytes.
These form the neurovascular unit (NVU), with endothelial
cells being the primary cells of the BBB that interact with
the CTCs (Fig. 1) [12].
Astrocytes are glial cells in the central nervous
system that are essential components of the blood brain bar-
rier [10]. These cells maintain healthy BBB integrity by
secreting factors that form and maintain strong tight junc-
tional complexes between endothelial cells [11]. The as-
trocytes, reside adjacent to the endothelium, with their end
feet almost entirely covering the abluminal membrane of
the cerebral capillaries [11]. Astrocyte processes at the en-
dothelium form an additional barrier, the glia limitans, by
the formation of gap junctions and tight junctions between
neighbouring astrocytic projections [13]. The astrocytic
end feet tightly connect to the endothelium through specific
interactions between the basal lamina and ECM [14]. Per-
icytes also lie in close contact with the abluminal side and
are intimately associated with astrocytic end feet [13]. Dur-
ing development, pericytes coat the endothelial vasculature
to produce a basal lamina that promotes accumulation of
astrocytic end feet around the endothelium [13]. Due to
this intimate relationship, both astrocytes and pericytes in
the BBB play vital roles in maintaining barrier integrity and
regulating permeability [11].
592
4. Tumour metastasis and the endothelium
Successful cerebral secondary colonisation re-
quires CTCs to adhere to and transmigrate through the cere-
bral vascular endothelium, invade the brain parenchyma,
proliferate and form secondary lesions [15]. However, not
all cancers have the propensity to enter the brain. There is
evidence that certain types of cancers such as breast, lung
andmelanoma are indeedmore prone tometastasising to the
brain. For instance, patients with Her-2 positive metastatic
breast cancer treated with trastuzumab are two-folds more
likely to have brainmetastasis than other breast cancer types
[16]. A similar observationwas also found inmelanoma pa-
tients treatedwith EGFRkinase inhibitor gefitinib. Interest-
ingly, overexpression of Stat3 in resected human melanoma
brain metastases suggested a preferential migratory effect
of cancer cells into the brain parenchyma [17]. Stat3 ex-
pression also increased angiogenesis and invasion [17]. In-
terestingly, elevated levels of activated leukocyte cell ad-
hesion molecule (ALCAM) in non-small-cell lung cancer
(NSCLC) resulted in an enhanced brain metastasis forma-
tion by increased tumour cell dissemination and interaction
with BBB endothelium [18].
Additionally, breast cancer cells express-
ing genes including prostaglandin synthesising en-
zyme cyclooxygenase-2, MMP1, angiopoietin-like 4
(ANGPTL4), latent TGF-beta1 binding protein (LTBP1),
epidermal growth factor receptor (EGFR) ligand HBEGF
and fascin-1 were shown to enhance brain metastasis via
producing pro-metastatic phenomenon such as inflamma-
tion, invasion and cancer cell motility [19]. Moreover,
expression of α2,6-sialyltransferase ST6GALNAC5
showed an increased adhesion to brain endothelial cells
and thereby, enhanced transmigration of breast cancer cells
through the BBB [19].
In a study investigating the role of truncated
glioma-associated oncogene homolog 1 (TGLI1) revealed
that its high expression results in increased breast cancer
metastasis to the brain [20]. TGLI1 resulted in an acti-
vation of stemness genes CD44, Nanog, Sox2 and OCT4
in radioresistant cancer stem and metastasis-initiating cells,
and through activation of astrocytes, this TGLT1 enhanced
brain metastasis [20]. Interestingly, T-cell-induction of
Guanylate-Binding Protein 1 expression in oestrogen recep-
tor negative breast cancer cells resulted in preferential seed-
ing to the brain, which could be a novel targeting strategy
for immunotherapy [20].
Nevertheless, once at the interface of the BTB,
through key interactions, CTCs attach to the endothelium
lining, alter the normal physiology of the cerebral vas-
culature to a pro-tumorigenic state and migrate through
the BBB. This metastatic cascade is believed to mirror
leukocyte transmigration through the BBB during inflam-
mation [21]. Initial leukocyte rolling and adhesion at the
cerebral endothelium is mediated via E-selectin adhesion
molecules, followed by activation, arrest, crawling and
subsequent migration mediated via intercellular adhesion
molecule (ICAM-1) and vascular cell adhesion molecule
(VCAM-1) [22]. This raised the possibility that the same
adhesion molecules also facilitate and mediate extravasa-
tion of CTCs metastasizing to the brain. Previous studies
illustrate that direct interactions between tumour cell secre-
tions and the cerebral endothelium facilitates the initial ad-
hesion and arrest of metastatic tumour cells. For instance,
Soto et al. [23] demonstrated that the same endothelial ad-
hesionmolecules E-selectin, ICAM-1 andVCAM-1 associ-
ated with leukocyte trafficking are upregulated on the cere-
bral endothelium after injection of metastatic breast cancer
cells, with the cells overexpressing the natural ligands to the
adhesion molecules.
Rai et al. [24] showed that non-small-cell lung
carcinoma (NSCLC) cell lines, A549 and SK-MES-1, se-
crete specific pro-metastatic proteins that directly alter the
integrity of the cerebral endothelial glycocalyx. The en-
dothelial glycocalyx is a dense intra-luminal layer lining the
healthy cerebral vascular endothelium connected via pro-
teoglycans and glycoproteins forming a mesh network of
soluble plasma- and endothelium- derived molecules [25].
The glycocalyx contributes to the maintenance of vascu-
lar homeostasis by forming an electrical barrier and regu-
lating vascular permeability [26]. This limits the leakage
of macromolecules into the capillaries and regulates adhe-
sion of circulating leukocytes to the cerebral vascular en-
dothelium [27]. Embedded within the glycocalyx are the
same adhesion molecules ICAM1, VCAM1 and E-selectin
observed in leukocyte extravasation [24]. The A549 and
SK-MES-1 cell line secretome consists of inflammatory cy-
tokine tumour necrosis factor-alpha (TNF-α), cathepsin L
(CL), cystatin C (CC), vascular endothelial growth factor
(VEGF) and insulin-like growth factor binding protein-7
(IGFBP-7). These aid in tumour cell growth and metasta-
sis through increasing endothelial surface E-selectin levels
[24]. Moreover, TNF-α induced adhesion of A549 and SK-
MES-1 lung cancer cell lines to cerebral endothelial cells by
3.6- and 5.3-folds respectively [24]. In addition, the tumour
cell secretome also contains hyaluronidase enzymes that di-
rectly degrade the glycocalyx monolayer [28]. Shredding
of the glycocalyx coincides with enhanced surface levels
of the adhesion molecules E-selectin, ICAM1 and VCAM1
which in turn facilitates rapid adhesion of lung tumour
cells to the cerebral endothelium, the first step to metastatic
transmigration and cerebral colonisation [24]. Supporting
this, Constantinescu et al. [29], observed that degrada-
tion of the endothelial glycocalyx in a pro-inflammatory
microenvironment also enhances leukocyte immobilization
and adhesion at the endothelium. These data suggest that
the lung cancer cells secrete factors that directly degrade the
cerebral endothelial glycocalyx, exposing embedded adhe-
sion molecules, and thus facilitating their own adhesion and
subsequent extravasation across the BBB.
Due to this complex structure and crosstalk within
the NVU in the tumour microenvironment, with endothe-
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lial cells playing a direct role in metastasis, it is crucial to
further understand the specific contributory factors of as-
trocytic end feet and the astrocyte secretome on BBB phys-
iology and their role in the BTB.
5. Role of Astrocytes in the BBB-CTC
interface
During early cerebral colonisation, reactive astro-
cytes secrete plasminogen activator, an anti-metastatic fac-
tor, to inhibit the invading cancer cells [30, 31]). Plasmin
induces conversion of membrane-bound astrocytic FasL
into an apoptotic signal for cancer cells and inactivation
of axon pathfinding molecule L1CAM1 that cancer cells
utilise to spread along the brain capillary [31]. Inter-
estingly, these invading cancer cells in the perivascular
space secrete serpins to shield this astrocyte-induced de-
fence. However, later on, within the developing cancer mi-
croenvironment, astrocytes instead play a pro-tumourigenic
role. For instance, earlier studies demonstrate a direct pro-
metastatic influence of astrocytes in co-culture with PC14-
PE6 lung tumour cells [32], and more recently it has been
reported that astrocytes produce and secrete matrix metallo-
proteinase enzymes -2 and -9 (MMP-2/-9) in the presence
of tumour cells that degrade and remodel local ECM, al-
lowing tumour invasion. Moreover, these cells were also
shown to induce cancer cell proliferation and chemopro-
tection by producing pro-inflammatory cytokines IL-6 and
TNF-α [33].
More specifically, Wang et al. [34] investigated
the hypothesis that astrocyte secretions play a direct role in
tumour cell metastasis to the brain. MDA-MB-231 breast
cancer cells, sarcoma 180 (S180) cell lines and lung adeno-
carcinoma (H2030) cells were incubated in astrocytic con-
ditioned media from neonatal rats [34]. The Boyden cham-
ber migration assay showed increased tumour cell migra-
tion in response to astrocytic conditioned media (CM), with
approximately 200 invadingH2030 cells with astrocyte CM
compared to 0 for the control without CM, suggesting that
factors within the astrocytic secretome play a role in can-
cer metastasis [34] (Table 1, Ref. [34–40]). These findings
were directly supported by more recent data demonstrating
that direct application of astrocytic conditioned medium to
MDA-MB-231 metastatic breast cancer cells and MCF10A
healthy breast epithelial cells significantly increased inva-
siveness and velocity of migration of both cell types [41].
Additionally, it was observed that the astrocyte secretome
also directly alters morphology of both cell types, form-
ing an elongated and enlarged cellular structure in compar-
ison to control cancer cells without astrocytic conditioned
medium [41]. It has been shown that breast cancer cells
migrate through the BBB with the adoption of an elongated
morphology [4]. This provides a direct link between astro-
cytes and metastatic cancer cell migration, with the pres-
ence of astrocytic secretome facilitating and enhancing tu-
mour cell and healthy epithelial cell migration [41], sug-
gesting this potential is present in the healthy brain. There-
fore, astrocytes play a direct role in tumour cell metastasis,
perhaps before any potential signalling from tumour cells
by increasing transmigration and altering tumour cell mor-
phology of both tumour cells and healthy epithelial cells to
a highly favourable phenotype for extravasation and subse-
quent secondary cerebral colonisation of the brain.
To investigate the composition of the astrocytic
secretome that contributes to the invasiveness of tumour
cells, the astrocytic conditioned media was treated with
a range of MMP inhibitors [34]. MMP’s are a group
of enzymes known to be implicated in cancer metastasis
and tumour invasiveness, particularly MMP-2 and MMP-
9 that directly degrade collagen and protein components
of the ECM and are secreted by both astrocytes and tu-
mour cells [42]. Astrocytes induce the cleavage of inac-
tive pro-MMP-2 and pro-MMP-9 secreted by tumour cells
to the active form which degrades collagen IV present in
the basement membrane of the BBB, subsequently remod-
elling the ECM and increasing permeability and enhancing
glioma, breast and lung tumour invasiveness to the brain
[34]. This is supported by recent studies observing reduced
collagen IV in the basement membrane of the BTB within
the metastatic cancer microenvironment [43]. Astrocytes
indirectly increase the activation of plasmin, a protease,
from plasminogen that cleaves and activates tumour cell de-
rived MMPs via interaction with the urokinase plasmino-
gen activator (uPA) [44] (Fig. 2). It has also been shown
that reactive astrocytes upregulate MMP secretions specif-
ically within the tumour microenvironment, suggesting a
link whereby astrocyte secretions of MMPs in particular,
are increased in response to extravasating tumour cell se-
cretions [45], including interleukin-8 (IL-8), plasminogen
activator inhibitor-1 (PAI-1) and macrophage migration in-
hibitory factor (MIF) that activate the astrocytes and in-
duce upregulation of MMPs. In the pathological state, as-
trocytes are activated and categorised by the upregulated
presence of intermediate filament glial fibrillary acidic pro-
tein (GFAP) and are termed “reactive astrocytes” [46]. This
response to brain insult is known as astrogliosis with astro-
cytes upregulating GFAP and pro-inflammatory cytokines
and chemokines to induce neuroinflammation [37]. The
astrocyte culture medium with MMP inhibitors was added
to an invasion assay with S180 and H2030 cell lines that
resulted in a significant reduction in cancer cell invasion.
This was further tested in vivo via the injection of astrocyte-
conditioned tumour cells into the left ventricle of the heart
in immunodeficient mice to directly enter the circulation
to the brain and access the cerebral microenvironment.
Astrocyte-conditioned tumour cells demonstrated a more
severe tumour metastasis and invaded the brain earlier than
astrocyte conditioned tumour cells treated with anMMP in-
hibitor suggesting a critical role of astrocytes and MMP
secretions in the induction of tumour cell transmigration
[34]. These findings were supported by recent data demon-
strating that inhibition of MMPs within astrocyte culture
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Table 1. Summary of astrocyte secretions in response to trauma/cancer microenvironment aiding the metastatic cascade.
Astrocyte secretion Cell line Function Pathology Reference





CXCL10 sBT-RMS Inflammation and invasion Cancer [35]
TNF-α PBMC, NSCLC, HARA-B Inflammation and proliferation Cancer, Diabetes [36]




IFN-α MDA231-BrM2, ErbB2-BrM, H2030-
BrM3
Inflammation and proliferation Cancer [38]
IL-6 HARA-B Inflammation and proliferation Cancer [36]
IL-1β HARA-B Inflammation and proliferation Cancer [36]
Polyunsaturated fatty acids BrM (WM4265.2, WM4265.2-BrM1) Pro-metastatic and proliferation Cancer [39]
AEG-1 NSCLC Upregulates release of MMPs Cancer [40]
Fig. 2. Astrocytes facilitate invasion of circulating tumour cells (CTCs). Astrocytes produce matrix metalloproteinases (MMPs) and induce cleavage
of tumour derived MMP-2/MMP-9 via activation of plasmin through interactions with urokinase-type plasminogen activator (UPA). Upregulation of
astrocyte elevated gene 1 (AEG-1) enhances release of MMP’s into tumour microenvironment. Uptake of tumour cell derived extracellular vesicles into
astrocytes downregulates expression of tissue inhibitors ofMMPs (TIMP-2), subsequently diminishing modulation ofMMP expression. Astrocyte derived
CXCL10 chemokine upregulates the receptor, CXCR3, on CTCs to enhance chemoattraction and migration of tumour cells.
medium reduced the migratory effects of MDA-MB-231
breast cancer cells in a dose dependent manner [41]. There-
fore, astrocytes in the tumour microenvironment not only
directly alter morphology and metastatic potential of tu-
mour cells and healthy epithelial cells prior to tumour cell
signalling, but also simultaneously secreteMMPs and inter-
act with tumour cell MMP secretions to facilitate extravasa-
tion. This suggests that MMP’s are an essential component
of astrocytic and tumour cell secretions in the cancer mi-
croenvironment that facilitate transmigration.
Sun et al. [47] demonstrated that overexpression
of astrocyte elevated gene-1 (AEG-1) correlates with high
expression and activation of MMP-9. This subsequently
enhances tumour invasiveness and metastasis, emphasis-
ing the role that astrocytes play in facilitating tumour cell
migration. Notably, NSCLC cells engineered to express
AEG-1 displayed high levels of MMP-9 correlating to in-
creased invasiveness compared with control [47]. Further-
more, Ding et al. [48] reported that overexpression of AEG-
1 also increases lung tumour cell angiogenesis and growth.
More recently, Li et al. [40] showed that knockout of AEG-
1 inhibited proliferation, migration and invasion of A549
lung cancer cell lines, with overexpression of AEG-1 res-
cuing this inhibition. This suggests that astrocytes not only
secrete MMP’s and cleave pro-MMP’s in the cancer cell se-
cretome, facilitating the degradation of the BBB, but also
overexpress AEG-1which subsequently upregulatesMMP-
9 expression in the tumour microenvironment and promotes
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tumour angiogenesis and migration (Fig. 2). Beyond this,
Morad et al. [49] demonstrated that extracellular vesicles
(EV) derived from metastatic breast cancer cells, follow-
ing transcytosis across the BBB, can be internalized by sur-
rounding astrocytes via endocytosis. This internalization
modulates expression of astrocyte derived MMPs and tis-
sue inhibitors of MMPS (TIMPs) to favour a pro-metastatic
tumour microenvironment. Interestingly, metastatic breast
cancer EV’s, once internalized by astrocytes, downregulate
astrocytic TIMP-2 and in turn reduce inhibition of MMP-
2 function on the degradation of the basement membrane
of the BBB [49] (Fig. 2). This further highlights a sig-
nificant role of astrocytes in the facilitation of metastasis,
with breast cancer cell EV’s reprogramming astrocytes to
reduce modulation of MMP activity through TIMPs. This
mechanism along with a strong upregulation of reactive as-
trocyte derived MMP’s specifically within the cancer mi-
croenvironment in response to cancer cell secretions sub-
sequently enhances MMP remodelling of the ECM to cre-
ate a highly favourable metastatic niche for extravasation.
An additional mechanism that promotes brain metastasis
through astrocyte-CTC EV crosstalk is the transfer of ex-
osomal microRNAs from astrocytes to CTCs specifically
in the cerebral tumour microenvironment. This transfer
downregulates PTEN, a vital tumour suppressor, and ulti-
mately promotes tumour cell survival in the brain [50]. This
demonstrates both astrocytes andCTCderived EVs enhanc-
ing migration as well as diminishing tumour suppression in
the brain.
Therefore, astrocytes play a pivotal role in pro-
moting transmigration of tumour cells across the BBB as
well as angiogenesis, growth and survival of tumour cells
once they invaded the brain parenchyma. However, Wang
et al. [34] observed only a partial inhibition of cancer cell
migration with MMP antibodies, suggesting MMP-2/-9 are
not the sole factors within the astrocyte secretome aiding
cancer cell migration. Despite this, these authors provide
evidence for astrocytes facilitating cancer cell migration in
metastasis, reacting to and cleavingMMPs from cancer cell
secretions and permitting extravasation.
In addition, it is well established that inflamma-
tion fosters proliferation and migration of tumour cells,
with the tumour microenvironment being predominantly
orchestrated by astrocyte-derived inflammatory cytokines
[51], which induces the metastatic process. As leuko-
cytes use parallel trans-endothelial migratory mechanisms
tometastatic cancer cells, this drives the proposal that astro-
cytic pro-inflammatory cytokine secretions in response to
CTCs may also support and facilitate trans-endothelial mi-
gration and ultimate secondary colonisation of tumour cells
in the brain [52]. For instance, Doron et al. [35], provided
evidence of circulating metastatic melanoma cells hijack-
ing the astrocyte protective inflammatory response to aid in
metastasis. CXCL10 is a chemokine secreted by astrocytes
in the tumour microenvironment as a protective mecha-
nism during metastasis. However, CTCs exploit this mech-
anism to their advantage, with upregulation of astrocyte de-
rived CXCL10 in the metastatic environment enhancing tu-
mour cell migration towards astrocytes [35]. The authors
observed an upregulation of CXCR3, the CXCL10 recep-
tor, in brain-tropic melanoma cells, with overexpression of
CXCR3 in vivo enhancing chemoattraction of melanoma
cells and formation of metastases [35] (Fig. 2). This pro-
vides further evidence of CTCs directly manipulating as-
trocytes in the tumour microenvironment to favour and fa-
cilitate metastasis.
6. Astrocytes promote cancer cell
proliferation
Migration, proliferation and invasion are key steps
in tumour growth and metastasis which are dependent on
crosstalk between CTCs and the brain microenvironment.
Invading tumour cells induce both mechanical (contact
inhibition by cadherin and β-catenin dysregulation) and
chemical (by secreting cytokines, e.g., IL-8, plasminogen
activator inhibitor-1, etc.) disturbances and thus result-
ing in astrocytic disruption in the brain, leading to astro-
cytic activation (reviewed in [53]). Since astrocytes are
able to induce tumour cell migration, their potential role in
cell proliferation has also been investigated. It has been
shown that astrocytes localize around metastasising can-
cer cells and offer a protective role throughout the inva-
sion process and formation of secondary lesions in the brain
[52]. To further investigate the potential role of astro-
cytes in cancer cell proliferation and survival post migra-
tion, Seike et al. [36] analysed co-cultures of astrocytes
and human lung cancer-derived cells (HARA-B) in mice in
vivo. The authors demonstrated that HARA-B cells secrete
tumour-cell oriented factors, including IL-8, PAI-1 and
MIF, which activate surrounding astrocytes accumulated
around the metastatic foci. 4–6 weeks post inoculation of
HARA-B cells into the cardiac ventricle in mice, metastatic
foci of different sizes were found throughout the brain,
with higher accumulation of GFAP-positive astrocytes cor-
related to larger tumour size; demonstrating a positive rela-
tionship between reactive astrocytes and metastatic tumour
cells in the tumour microenvironment [36]. These reactive
astrocytes subsequently secreted the cytokines interleukin-
6 and -1β (IL-6, IL-1β) and TNF-α which induced tumour
cell proliferation, with TNF-α mRNA expression in astro-
cytes being the highest in response to lung tumour cell se-
cretome exposure [36] (Fig. 3). These data suggest that
TNF-α is a key component not only for tumour cell ad-
hesion at the endothelium but also for proliferation of tu-
mour cells in the brain. A positive correlation between
HARA-B cell and astrocyte ratio and rate of proliferation
was observed, with HARA-B cells co-cultured with astro-
cytes showing a 3-fold increase in proliferation rate com-
pared to either HARA-B cells or astrocytes alone [36]. This
demonstrates a mutual relationship between astrocytes and
tumour cells to induce and facilitate tumour cell prolifera-
596
Fig. 3. Astrocytes facilitate tumour cell proliferation. Tumour cell derived interleukin 8 (IL-8), plasminogen activator inhibitor 1 (PAI-1) and migration
inhibitory factor (MIF) activate surrounding astrocytes which subsequently secrete pro-proliferative factors interleukin 6 (IL-6), interleukin 1β (IL-1β)
and tumour necrosis factor α (TNF-α). Tumour cells and reactive astrocytes engage in connexin 43 (Cx43) junctions to allow the transfer of cGAMP to
astrocytes from the tumour cells. This activates the astrocytic STING pathway intended as a protective immune response with the secretion of TNF-α and
interferon-alpha (IFN-α) which activate the pro-proliferative signal transducer and activator of transcription 1 (STAT-1) and NF-kB pathways in tumour
cells. Astrocyte derived fatty acid secretions in the tumour microenvironment activate the pro-proliferative peroxisome proliferator-activated receptor
gamma (PPARγ) pathway in tumour cells. Tumour cell secretions activate STAT-3 in reactive astrocytes, subsequently reducing immune cell infiltration
into the tumour and supporting tumour cell growth and survival.
tion, with unstimulated astrocytes and tumour cells showing
significantly reduced proliferation on their own. Thus, pro-
viding direct evidence of astrocyte cytokine secretions in
the metastatic microenvironment driving tumour cell pro-
liferation.
Seike et al. [36] went further to investigate
whether the mutual relationship between astrocytes and
lung cancer cells was specific to the HARA-B cell line.
Primary cultured astrocytes were co-cultured with 3 addi-
tional cell lines derived from human squamous cell carci-
noma (QG56, EBC-1) and NSCLC (PC-9). Proliferation
of the additional lung cancer cell lines also significantly in-
creased in the presence of astrocytes, with 350% cell pro-
liferation for HARA-B cells, 200% proliferation for QG56
cells, almost 500% proliferation for EBC-1 cells and 150%
proliferation for PC9 cells compared to basal proliferation
(100%) without astrocytes [36]. This further supports the
notion that astrocytes and tumour cells have a mutual rela-
tionship whereby reciprocal stimulation and cross talk pro-
motes proliferation and survival of lung tumour cells in the
brain [36]. Furthermore, different concentrations of recom-
binant mouse cytokines (m), such as mIL-1β, mTNF-α and
mIL-6, and neutralizing antibodies were used to confirm the
effects of the astrocytic cytokines on lung tumour cell pro-
liferation. These cytokines increased tumour cell prolifera-
tion in a dose dependent manner, with 10 pg/mL of mIL-1β
increasing tumour cell proliferation by nearly 200% com-
pared with control (no mIL-1β) at 100%, and 500 pg/mL
of mTNF-α and mIL-6 increasing proliferation by approx-
imately 150% compared with control with no cytokine at
100%. Additionally, neutralizing antibodies against mIL-
1β, mTNF-α and mIL-6 inhibited the growth promoting ef-
fect observed in the co-culture, and significantly decreased
HARA-B tumour cell proliferation [36]. This provides fur-
ther direct evidence of a relationship between lung tumour
cells and astrocytes, with astrocyte cytokine secretions re-
acting to and promoting proliferation of tumour cells, plac-
ing astrocytes in a critical role in the metastatic process.
In addition, Chen et al. [38] demonstrated that
lung carcinoma cells express protocadherin 7 (PCDH7) to
engage astrocytes in functional connexin 43 (Cx43) gap
junctions. These gap junctions allow lung tumour cells to
transfer the second messenger cGAMP to astrocytes which
activates the astrocytic immune cGAS-STING pathway.
This subsequently results in the release of inflammatory
cytokines from reactive astrocytes, including TNF-α and
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IFN-α, which activate the STAT-1 and NF-kB pathways in
CTCs, inducing proliferation and chemoprotection of tu-
mour cells [44] (Fig. 3). Despite STING being an immune
response with the role to initially suppress and reject tu-
mour growth, the subsequent astrocytic secretions interact
with CTCs and instead promote tumour survival. This cross
talk between astrocytes and tumour cells is supported by
data demonstrating that gap junctions between tumour cells
and astrocytes enable astrocyte-derived cyclic GMP-AMP
synthase and microRNAs to be transferred to tumour cells
to induce metastasis formation [4]. This supports previous
findings and confirms a reciprocal relationship between tu-
mour cells and astrocytes resulting in astrocytic activation
and subsequent cytokine secretions which directly facilitate
tumour cell growth in the brain [4]. Furthermore, Priego
et al. [54], demonstrated that proliferating tumour cells
in the brain secrete IL-6, epidermal growth factor (EGF)
and transforming growth-factor alpha (TGF-α) that acti-
vate the signal transducer and activator of transcription 3
(STAT3) in reactive astrocytes. These astrocytes then re-
duce the expression of a specific activationmarker onCD8+
T cells, subsequently reducing an immune response to the
metastatic foci. This creates a barrier of reactive astrocytes
around the tumour, reducing access from cytotoxic CD8+
T cells into the core of the tumour and allowing tumour cell
growth and survival in the brain [55] (Fig. 3).
Zou et al. [39], showed that metastatic melanoma
and breast cancer cell lines in astrocyte culture medium
also promoted cancer cell growth. Astrocytes surrounding
the metastatic foci in the brain naturally release polyun-
saturated fatty acids into the microenvironment to aid in
neuronal synaptic formation and function [39]. However,
these astrocyte-derived fatty acids are pro-metastatic and
activate the peroxisome proliferator-activated receptor γ
(PPARγ) signalling pathway in metastatic cancer cells.
PPARs are transcription factors activated by ligands, most
importantly polyunsaturated fatty acids, that bind to a per-
oxisome proliferator-activated receptor response element
(PPRE) to activate target genes. Subsequently, this PPARγ
signalling pathway activation in cancer cells by astrocyte
derived fatty acids was observed to be pro-proliferative [39]
(Fig. 3). Most importantly, PPARγ antagonism in vivo re-
versed astrocyte induced proliferation of cancer cells, pro-
viding a direct link between increased PPARγ signalling
and metastatic growth [39]. This suggests that cancer cells,
once migrated across the BBB, exploit the brain microen-
vironment, specifically the lipid rich environment provided
by astrocytes, to proliferate in the brain.
7. Astrocytes in the blood tumour barrier
Within the tumour microenvironment, the blood
brain barrier is disrupted and undergoes conformational
changes dependent on the progression of metastasis [43].
These physiological changes occur once metastases have
been established in the brain and characterise the blood tu-
mour barrier which is highly permeable compared to the
healthy BBB [13]. Such changes have been shown to fa-
cilitate and aid in the metastatic process by increasing BBB
permeability and the ability of cancer cells to extravasate
and invade the brain parenchyma [43]. The formation of the
BTB involves the accumulation of reactive astrocytes that
secrete pro-inflammatory cytokines [13]. Due to the com-
plex interactions within the NVU, astrocytes have the po-
tential to play a key role in cancer extravasation and metas-
tasis within the BTB. For example, aquaporin-4 (AQP-4)
is a water channel within the astrocytic end feet that cov-
ers the BBB basement membrane and aids in supplying
nutrients to surrounding neurons and maintaining vascu-
lar homeostasis and ionic regulation in the healthy brain
[56]. Additionally, AQP-4 is coexpressed with agrin, a pro-
teoglycan present on the basal lamina, which accumulates
around cerebral capillaries for BBB tightening [11]. How-
ever, a significant loss of AQP-4 at cerebral vessels at the
tumour interface at week 3 post-injection of A549 NSCLC
line was observed which persisted throughout the develop-
ment of mid- and late-stage metastasis, with a 12.18-fold
decrease in AQP-4 expression at week 6 [43]. This corre-
lates with the loss of agrin in human brain tumours which
could result in an increased permeability of the BBB [57].
Loss of aquaporin-4 has also been observed in breast can-
cer metastasis to the brain and relates to a loss of polariza-
tion of the astrocytic end feet at the BTB contributing to
the loss of BBB integrity caused by metastasising cells and
favouring their migration [43]. Aquaporins are key regula-
tors of BBB integrity, with studies demonstrating that up-
regulation of AQP-4 in vivo in gliomas compensates for re-
duced astrocytic end feet [58]. Furthermore, these findings
support observations of decreased levels of AQP-4 in as-
trocytic end feet in the BTB compared with control, with
a reduced and distal distribution of AQP-4 from the end
feet at the BTB not localized at the cerebral capillaries [59].
This suggests that not only is AQP-4 expression within as-
trocytic end feet significantly reduced in the metastatic tu-
mour microenvironment, but that the localization of the end
feet is altered and no longer polarized at cerebral blood ves-
sels. AQP-4 reduction is also associated with inflammation
[43], potentially induced by pro-inflammatory cytokines in
the tumour microenvironment. This suggests that altered
astrocyte physiology within the BTB is linked to specific
factors released by tumour cells at the metastatic interface
and contributes to increased BBB permeability, ultimately
aiding the metastatic cascade of cancer cells to the brain.
Furthermore, the absence of astrocytes at the BTB
is correlated with down-regulated expression of Mfsd2a,
a fatty acid transporter in the cerebral endothelium [60].
In the healthy brain, Mfsd2a mediates transcytosis within
endothelial cells, with murine Mfsd2a knockout studies
disrupting the cerebral vascular endothelium and increas-
ing transcellular transport and permeability [60]. These
findings highlight that astrocyte interactions with the cere-
bral endothelium are altered in the tumour microenviron-
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ment, subsequently degrading BBB integrity and increas-
ing the permeability for cancer cell invasion to the brain
parenchyma. Therefore, astrocytes have a significant role
in the facilitation of cancer metastasis to the brain, with the
tumour microenvironment directly altering astrocyte phys-
iology and displacing astrocytic end feet to enhance entry
into the brain.
8. Pericytes and metastasis
To provide a complete picture of the tumour mi-
croenvironment at the BTB interface for metastasis, it is
essential to include contributions and potential metastatic
facilitation from pericytes. Pericytes are multi-functional
mural cells that abluminally partially line endothelial cells,
coating capillaries and venules throughout the body, with
the highest density of pericytes found at cerebral capil-
laries within the NVU of the BBB [61]. Pericytes are
vital in regulating expression of tight junction compo-
nents and maintaining BBB integrity and vascular tone
[62]. Platelet-derived growth factor receptor-β protein
(PDGFR-β) within pericytes has a crucial role in modu-
lating homeostasis, vascular tone and integrity of the BBB
[43]. Platelet-derived growth factor-β (PDGF-β) is se-
creted into the basement membrane of the BBB from cere-
bral endothelial cells, this recruits pericyte coverage of
the BBB via their PDGFR-β receptors [59]. Importantly,
pericyte-deficient mutant mice displayed significantly in-
creased BBB permeability to different weighted molecular
tracers [13], and PDGFR-β knockout mice lacked pericyte
populations and had a disrupted BBB [59]. Moreover, over-
expression of PDGFR-β increases pericyte accumulation
and tumour growth, as well as maintaining vessel integrity
[63].
Uzunalli et al. [43] visualised the BTB in immun-
odeficient mice over 6 weeks using immunofluorescence
microscopy after intracardial injection of NSCLC cell lines.
At late-stage NSCLC metastasis in week 6, there was a
2.78-fold decrease in PDGFR-β-positive pericytes of the
BTB compared to the healthy BBB, with diminished ex-
pression of the protein observed from mid-stage metastasis
in week 3 onwards [43]. As PDGFR-β knockout studies
demonstrate enhanced BBB permeability, this highlights a
critical role of pericytes in modulating BBB integrity and
vascular transport [64]. Furthermore, a time-dependent in-
crease of desmin expression in pericytes covering the cere-
bral endothelium was observed in the BTB compared to the
BBB with a 3.95-fold increase in desmin positive pericytes
in week 5 post intracardial injection of cancer cells [43].
Desmin is a type III intermediate filament protein present
in a specific subset of pericytes within the CNS, with over-
expression of desmin correlating to increased BBB perme-
ability [59]. These findings highlight significant alterations
in pericyte physiology in the tumour microenvironment of
metastasis disrupting BBB integrity and vascular tone sub-
sequently facilitating and enhancing tumour cell extravasa-
tion into the brain, leading to further tumour cell-astrocyte
interaction. Moreover, these findings were supported by
previous data displaying significant disruption in PDGFR-
β and desmin positive pericyte subpopulations in the BTB
of breast cancer brain metastasis [59]. More specifically,
Lyle et al. [59] injected breast cancer cell lines into the
left ventricle of immunocompromised mice and used up-
take of Texas Red dextran as a permeability marker of the
BBB. Breast cancer cell metastasis at low BTB permeabil-
ity was compared with metastasis at high BTB permeability
and a significant increase in expression of desmin positive
pericytes coverage of the cerebral endothelia was observed
associated with high BTB permeability [59]. Therefore, in
addition to astrocytes, pericytes also play an important role
in the facilitation of extravasation of tumour cells through
the BBB.
9. Potential for future studies
It is known that in the cancer microenvironment
there is an upregulation of endothelial adhesion molecules
for the arrest and subsequent migration of tumour cells
across the BBB [24]. However, it is not known whether the
astrocyte secretome directly interacts with the endothelium
of the BBB during metastasis and upregulates expression of
the same adhesionmolecules. These events are vital for aid-
ing CTC migration at the BTB interface, and such adhesion
molecules provide a potential therapeutic target outside the
brain parenchyma. Recent studies provide evidence of po-
tential contributions from astrocytic secretome interacting
with the cerebral endothelium and upregulating adhesion
molecules for transmigration. For instance, Spampinato et
al. [65] demonstrated that the inflammatory cytokine secre-
tions, including TNF-α, from astrocytes enhanced expres-
sion of ICAM1 for the transendothelial migration of periph-
eral blood mononuclear cells (PBMCs). This suggests that
astrocytes interact with, andmodify endothelial physiology,
with reactive astrocyte pro-inflammatory secretions in re-
sponse to cancer cell secretions enhancing surface levels
of an essential endothelial adhesion molecule for extrava-
sation of CTCs into the brain. Incentive is therefore pro-
vided to further investigate the potential metastatic facilita-
tion from astrocytes and interactions with endothelial adhe-
sion molecules. An additional hypothesis to investigate in-
volving astrocytes and metastasis is the link between astro-
cytic tenascin-C within the tumour microenvironment and
metastatic tumour cell invasion and proliferation. Tenascin-
C (TNC) is an ECM glycoprotein that is downregulated in
healthy tissues but overexpressed with GFAP in reactive as-
trocytes in the pathological brain and is negatively corre-
lated to the presence of AQP-4 in astrocytic end feet [37].
TNC is also highly expressed in the tumour microenviron-
ment of malignant lung, breast and colon cancer [66]. It has
been observed that tenascin-C knockout mice are associated
with the inhibition of MMP-9 induction and decreased per-
meability of the BBB, with TNC expression upregulating
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MMPs in cancer cells [67]. The exact mechanism for this is
unknown; however, this provides a link between astrocytes
and the BBB. Specifically since TNC expression is associ-
ated with cancer cell secretion such as MMPs, it is possi-
ble that increased secretions of TNC from astrocytes in the
cancer microenvironment may facilitate BBB breakdown
in metastasis via MMPs. Additionally, within acute mul-
tiple sclerosis plaques, there is a significant loss of TNC,
reflecting enzymatic degradation of ECM components and
breakdown of the BBB [68]. As with metastasis, astroglio-
sis is a prominent feature in multiple sclerosis lesions, and
this loss of TNC may be via MMPs that directly degrade
the ECM and subsequently breakdown the BBB and facil-
itate leukocyte extravasation (review on astrogliosis [69]).
Furthermore, Xia et al. [66] observed that TNC expres-
sion promotes invasion of glioblastoma cells, with reduced
TNC within the tumour microenvironment inhibiting tu-
mour invasiveness but increasing tumour cell proliferation
[66]. These studies demonstrate an influence of TNC ex-
pression on tumour cell behaviour correlating to a decrease
in AQP-4 in the BTB, with a link between TNC and MMP
secretions degrading the BBB for leukocyte and cancer cell
extravasation in brain metastases. Currently there are no
knockout models which can be used to test this hypothe-
sis with TNC and AQP-4, however these findings provide
incentive for further research as to whether targeting TNC
could be a potential novel therapeutic in brain metastasis.
Furthermore, patient-derived cancer models are
being developed with researchers recently establishing a
patient-derived xenograft model system of NSCLC brain
metastases [7]. This is being developed with the aim to im-
prove therapeutic approaches to brain metastases. More-
over, further studies are currently being undertaken to in-
vestigate potential differential molecular crosstalk in en-
hancing brain metastasis and therapeutic targets. For in-
stance, in vitro 3D models mimicking the complex BBB
microenvironment is currently being developed to closely
study the crosstalk between different cell types, barrier
function and drug design [70–72]. Lee et al. [73] have re-
cently developed a microfluidic 3D in vitro system of the
BBB by adopting the CNS angiogenesis model. This model
successfully showed in vivo-like interactions between per-
icytes, human brain microvascular endothelial cells and as-
trocytes, including expressions of tight junctions. Addition-
ally, the authors reported drug penetration via the efflux
system that exists in the BBB, a promising step to study-
ing mechanisms of drug delivery in vitro in a CNS model
[73]. Moving forward, this model could be developed fur-
ther to study pathologies by mimicking a damaged BBB to
study extravasation of tumour cells into the brain, generat-
ing physiological shear pressure which has been shown to
regulate vascular permeability and by measuring TEER as
another metric of BBB function [74, 75].
10. Conclusions
Within the healthy brain, the neurovascular unit
is essential in maintaining vascular endothelial homeosta-
sis, permeability and integrity. However, in the cancer mi-
croenvironment, this interface is disrupted, with alterations
in astrocyte, pericytes and endothelial properties charac-
terizing the BTB. Circulating tumour cells secrete a com-
plex mix of factors that directly interact with surrounding
astrocytes, activating these astrocytes and inducing pro-
metastatic secretions that aid in cancer cell adhesion, migra-
tion and proliferation. Metastatic tumour cells exploit sur-
rounding astrocytes to facilitate extravasation and survival
in the brain, forming a mutual relationship, with reciprocal
stimulation being pivotal for tumour growth and survival.
Understanding this complex interface of astrocytes, peri-
cytes and cerebral endothelial cells and its manipulation by
tumour cells in the tumour microenvironment will provide
additional targets for metastatic treatment.
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